Galera Therapeutics Shares Rise Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data
Galera Therapeutics, Inc. (NASDAQ: GRTX) shares jumped more than 115% on Tuesday after the clinical stage biopharmaceutical company that corrected results from its Phase 3 ROMAN trial of avasopasem for the treatment of RT-induced severe oral mucositis (SOM) in patients...